This suggests that the use of the iBoost technology can improve the underlying cytotoxic T cell responses and thus, increase protection in vaccinated individuals, as CD8+ T cells specific for certain coronavirus epitopes correlate with the development of mild COVID-19 (Schmidt and Varga, 2018). This evidence concerns the gene CD8A and COVID-19.